El año pasado, Halozyme Therapeutics Inc generó 867.84M USD en su segmento con mejor rendimiento, Royalties. United States realizó la mayor aportación, representando 822.98M USD el año pasado.

Por negocio

Ingresos operativos

Proporción

Anual

Anual

Trimestral

Royalties

Sales of proprietary products

Sales of bulk rHuPH20

Sales-based milestones

Sales of device partnered products

Event-based development and regulatory milestones and other fees

Upfront license fees

Device Licensing and development revenue

ENHANZE

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

Royalties

867.84M(62.14%)

570.99M(56.24%)

447.87M(54.01%)

360.48M(54.61%)

203.90M(45.99%)

88.60M(33.11%)

69.90M(35.66%)

Sales of proprietary products

194.61M(13.93%)

166.62M(16.41%)

130.83M(15.78%)

72.85M(11.04%)

23.26M(5.25%)

17.03M(6.36%)

17.00M(8.67%)

Sales of bulk rHuPH20

133.02M(9.52%)

86.33M(8.50%)

115.44M(13.92%)

82.08M(12.43%)

80.96M(18.26%)

38.24M(14.29%)

48.28M(24.64%)

Sales-based milestones

70.00M(5.01%)

30.00M(2.95%)

--(--)

10.00M(1.51%)

50.00M(11.28%)

15.00M(5.61%)

--(--)

Sales of device partnered products

48.81M(3.50%)

50.54M(4.98%)

54.58M(6.58%)

36.10M(5.47%)

--(--)

Event-based development and regulatory milestones and other fees

47.00M(3.37%)

72.50M(7.14%)

69.00M(8.32%)

59.00M(8.94%)

42.00M(9.47%)

69.50M(25.97%)

5.50M(2.81%)

Upfront license fees

18.47M(1.32%)

27.00M(2.66%)

2.00M(0.24%)

30.00M(4.54%)

42.00M(9.47%)

37.26M(13.93%)

53.00M(27.04%)

Device Licensing and development revenue

16.86M(1.21%)

11.34M(1.12%)

9.53M(1.15%)

9.61M(1.46%)

1.19M(0.27%)

1.25M(0.47%)

1.54M(0.79%)

ENHANZE

--(--)

719.00K(0.27%)

768.00K(0.39%)

Por región

Ingresos operativos

Proporción

Anual

Anual

Trimestral

United States

Switzerland

Belgium

Japan

All other foreign

United States

Switzerland

Belgium

Ireland

FY2025

FY2024

FY2023

FY2022

United States

822.98M(58.93%)

--(--)

Switzerland

276.41M(19.79%)

--(--)

Belgium

217.52M(15.57%)

--(--)

Japan

46.37M(3.32%)

18.94M(1.87%)

15.10M(1.82%)

47.94M(7.26%)

All other foreign

33.33M(2.39%)

9.53M(0.94%)

19.58M(2.36%)

5.26M(0.80%)

United States

--(--)

690.46M(68.00%)

587.20M(70.81%)

437.99M(66.35%)

Switzerland

--(--)

212.39M(20.92%)

149.02M(17.97%)

166.84M(25.27%)

Belgium

--(--)

84.00M(8.27%)

58.35M(7.04%)

2.09M(0.32%)

Ireland

--(--)

3.00K(--)